Global Blood Therapeutics, Inc. (GBT) financial statements (2020 and earlier)

Company profile

Business Address 171 OYSTER POINT BLVD, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments302268338157275195342
Cash and cash equivalents302268338157275195342
Receivables3      
Inventory, net of allowances, customer advances and progress billings1      
Inventory1      
Prepaid expense9   6  
Other current assets    2  
Other undisclosed current assets312348328309202197127
Total current assets:628616667465486392470
Noncurrent Assets
Operating lease, right-of-use asset5314  
Property, plant and equipment27141213151717
Restricted cash and investments2222221
Other noncurrent assets1100000
Other undisclosed noncurrent assets8580871321149951
Total noncurrent assets:16811210214813211870
TOTAL ASSETS:796727769613618510539
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities70403831332620
Accounts payable11777653
Accrued liabilities41222318171411
Employee-related liabilities1810861076
Other liabilities2111111
Total current liabilities:71414032342721
Noncurrent Liabilities
Long-term debt and lease obligation14624     
Long-term debt, excluding current maturities74      
Operating lease, liability7224  
Liabilities, other than long-term debt0410111111
Other liabilities0410111111
Other undisclosed noncurrent liabilities  2424   
Total noncurrent liabilities:146282524111111
Total liabilities:217696557453833
Stockholders' equity
Stockholders' equity attributable to parent579658704557573472507
Common stock0000000
Additional paid in capital1,3171,3001,2811,0771,045895887
Accumulated other comprehensive income (loss)1111(0)(0)(0)
Accumulated deficit(739)(643)(578)(521)(472)(423)(380)
Total stockholders' equity:579658704557573472507
TOTAL LIABILITIES AND EQUITY:796727769613618510539

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues2      
Operating expenses(110)(69)(61)(53)(52)(45)(42)
Other undisclosed operating income10      
Operating loss:(99)(69)(61)(53)(52)(45)(42)
Nonoperating income
(Other Nonoperating income)
 434 22
Other undisclosed loss from continuing operations before equity method investments, income taxes(42)   (6)  
Loss from continuing operations before equity method investments, income taxes:(142)(65)(57)(49)(58)(43)(40)
Other undisclosed income from continuing operations before income taxes46   9  
Net loss:(96)(65)(57)(49)(49)(43)(40)
Other undisclosed net loss attributable to parent(0)   (0)  
Net loss available to common stockholders, diluted:(96)(65)(57)(49)(49)(43)(40)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(96)(65)(57)(49)(49)(43)(40)
Comprehensive loss:(96)(65)(57)(49)(49)(43)(40)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)110(0)0
Comprehensive loss, net of tax, attributable to parent:(96)(65)(57)(48)(49)(43)(40)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: